Top 10 drugs
Top 10 drugs 2023–24
- Aust Prescr 2024;47:194
- 17 December 2024
- DOI: 10.18773/austprescr.2024.048
Tables 1 to 3 show the top 10 drugs for the year 1 July 2023 to 30 June 2024. The figures are based on PBS and RPBS prescriptions from the date of supply.
Table 1 Top 10 PBS and RPBS drugs by DDD/1000 population/day
Drug | DDD/1000 population/day |
1. rosuvastatin |
84.59 |
2. atorvastatin |
80.72 |
3. amlodipine |
54.08 |
4. perindopril |
53.65 |
5. candesartan |
35.02 |
6. telmisartan |
34.10 |
7. sertraline |
30.64 |
8. escitalopram |
28.65 |
9. metformin |
28.32 |
10. irbesartan |
25.33 |
Table 2 Top 10 PBS and RPBS drugs by prescription counts
Drug | Prescriptions |
1. rosuvastatin |
17,020,106 |
2. atorvastatin |
11,877,199 |
3. pantoprazole |
10,836,323 |
4. esomeprazole |
8,270,226 |
5. perindopril |
6,979,326 |
6. escitalopram |
6,431,014 |
7. metformin |
6,168,095 |
8. sertraline |
6,041,182 |
9. amoxicillin |
5,190,911 |
10. cefalexin |
5,130,305 |
Table 3 Top 10 PBS and RPBS drugs by cost to government (does not include rebates)
Drug | Cost to government | Prescriptions |
1. pembrolizumab |
$580,519,979 |
68,148 |
2. elexacaftor+tezacaftor+ivacaftor with ivacaftor |
$568,739,037 |
26,609 |
3. nivolumab |
$449,363,401 |
62,276 |
4. ustekinumab |
$438,267,241 |
60,496 |
5. molnupiravir |
$430,190,110 |
371,952 |
6. aflibercept |
$427,003,953 |
436,779 |
7. dupilumab |
$368,349,053 |
214,577 |
8. apixaban |
$346,176,827 |
4,157,993 |
9. nirmatrelvir with ritonavir |
$325,856,114 |
270,376 |
10. denosumab |
$297,539,759 |
1,178,731 |
DDD defined daily dose
PBS Pharmaceutical Benefits Scheme
RPBS Repatriation Pharmaceutical Benefits Scheme
The prescription and DDD/1000 population/day figures include under co-payment (non-subsidised) prescriptions.
The cost figures are cost to government, excluding any patient contributions.
DDD/1000 population/day is a more useful measure of drug utilisation than prescription counts. It shows how many people in every thousand Australians are taking the standard dose of a drug every day. DDD includes use in combination products. The calculation is based on ABS 3101.0 – Australian Demographic Statistics for December 2023.
The tables do not include items dispensed under the Opioid Dependence Treatment (ODT) Community Pharmacy Program (buprenorphine, buprenorphine with naloxone, and methadone) due to differences in how these products are listed on the PBS compared to other products.
Prescription counts for some drugs may have been affected by the availability of 60-day PBS prescriptions. The dates on which 60-day prescriptions became available were 1 September 2023 for atorvastatin, perindopril and rosuvastatin, and 1 March 2024 for metformin.
Source: Department of Health and Aged Care, October 2024. © Commonwealth of Australia
Australian Prescriber welcomes Feedback.